Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Liabilities and Shareholders Equity: 2014-2025

Historic Liabilities and Shareholders Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $577.1 million.

  • Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity fell 25.23% to $577.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 3.41%. This contributed to the annual value of $742.4 million for FY2024, which is 51.38% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Liabilities and Shareholders Equity stood at $577.1 million for Q3 2025, which was down 0.89% from $582.3 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Liabilities and Shareholders Equity high stood at $771.9 million for Q3 2024, and its period low was $118.2 million during Q2 2021.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Liabilities and Shareholders Equity value was $582.3 million (recorded in 2025), while the average stood at $555.3 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity surged by 573.73% in 2021, and later dropped by 25.38% in 2023.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Liabilities and Shareholders Equity stood at $203.7 million in 2021, then soared by 113.58% to $435.1 million in 2022, then rose by 12.72% to $490.4 million in 2023, then surged by 51.38% to $742.4 million in 2024, then decreased by 25.23% to $577.1 million in 2025.
  • Its last three reported values are $577.1 million in Q3 2025, $582.3 million for Q2 2025, and $661.0 million during Q1 2025.